Migdal Insurance & Financial Holdings’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-801,589
| Closed | -$20.3M | – | 409 |
|
|
2025
Q1 | $20.3M | Buy |
801,589
+1,589
| +0.2% | +$41.6K | 0.29% | 63 |
|
|
2024
Q4 | $21.2M | Buy |
800,000
+795,933
| +19,571% | +$21.6M | 0.3% | 62 |
|
|
2024
Q3 | $118K | Buy |
4,067
+462
| +13% | +$13.5K | ﹤0.01% | 227 |
|
|
2024
Q2 | $100K | Buy |
+3,605
| New | +$99.3K | ﹤0.01% | 245 |
|
|
2024
Q1 | – | Sell |
-32,748
| Closed | -$943K | – | 441 |
|
|
2023
Q4 | $943K | Sell |
32,748
-1,761,741
| -98% | -$53.3M | 0.02% | 168 |
|
|
2023
Q3 | $59.5M | Buy |
1,794,489
+5,042
| +0.3% | +$178K | 1.27% | 26 |
|
|
2023
Q2 | $65.6M | Buy |
1,789,447
+932,540
| +109% | +$36.3M | 1.52% | 15 |
|
|
2023
Q1 | $35M | Buy |
856,907
+850,566
| +13,414% | +$36.7M | 0.77% | 38 |
|
|
2022
Q4 | $324K | Buy |
6,341
+1,291
| +26% | +$61.9K | 0.01% | 191 |
|
|
2022
Q3 | $224K | Sell |
5,050
-6,900
| -58% | -$335K | 0.01% | 215 |
|
|
2022
Q2 | $622K | Sell |
11,950
-1,911,000
| -99% | -$97.4M | 0.01% | 161 |
|
|
2022
Q1 | $99.6M | Buy |
1,922,950
+8,150
| +0.4% | +$423K | 1.74% | 17 |
|
|
2021
Q4 | $113M | Sell |
1,914,800
-22,195
| -1% | -$1.1M | 1.09% | 24 |
|
|
2021
Q3 | $83.3M | Buy |
1,936,995
+223,602
| +13% | +$9.91M | 0.88% | 36 |
|
|
2021
Q2 | $67.1M | Buy |
1,713,393
+1,691,842
| +7,850% | +$65.8M | 0.7% | 41 |
|
|
2021
Q1 | $781K | Buy |
21,551
+19,902
| +1,207% | +$707K | 0.01% | 266 |
|
|
2020
Q4 | $61K | Sell |
1,649
-249
| -13% | -$9.13K | ﹤0.01% | 488 |
|
|
2020
Q3 | $66K | Sell |
1,898
-680
| -26% | -$23.8K | ﹤0.01% | 529 |
|
|
2020
Q2 | $80K | Sell |
2,578
-16
| -0.6% | -$544 | ﹤0.01% | 448 |
|
|
2020
Q1 | $80K | Buy |
+2,594
| New | +$88.4K | ﹤0.01% | 419 |
|
|
2019
Q3 | – | Sell |
-676,612
| Closed | -$27.8M | – | 776 |
|
|
2019
Q2 | $27.8M | Sell |
676,612
-194,486
| -22% | -$7.72M | 0.71% | 37 |
|
|
2019
Q1 | $35.1M | Buy |
871,098
+407,551
| +88% | +$16.3M | 0.84% | 29 |
|
|
2018
Q4 | $19.2M | Sell |
463,547
-288,908
| -38% | -$12M | 0.43% | 47 |
|
|
2018
Q3 | $31.5M | Buy |
752,455
+25,972
| +4% | +$1,000K | 0.65% | 34 |
|
|
2018
Q2 | $25M | Buy |
726,483
+16,971
| +2% | +$580K | 0.59% | 40 |
|
|
2018
Q1 | $23.9M | Buy |
709,512
+875
| +0.1% | +$30.1K | 0.57% | 40 |
|
|
2017
Q4 | $24.4M | Buy |
708,637
+2,355
| +0.3% | +$80.3K | 0.6% | 44 |
|
|
2017
Q3 | $23.9M | Buy |
706,282
+4,785
| +0.7% | +$154K | 0.57% | 49 |
|
|
2017
Q2 | $22.4M | Sell |
701,497
-57,141
| -8% | -$1.8M | 0.51% | 48 |
|
|
2017
Q1 | $24.6M | Buy |
758,638
+2,491
| +0.3% | +$78.5K | 0.59% | 44 |
|
|
2016
Q4 | $23.3M | Buy |
756,147
+3,623
| +0.5% | +$111K | 0.59% | 36 |
|
|
2016
Q3 | $24.2M | Sell |
752,524
-7,613
| -1% | -$255K | 0.69% | 30 |
|
|
2016
Q2 | $25.4M | Sell |
760,137
-570,683
| -43% | -$18.2M | 0.7% | 33 |
|
|
2016
Q1 | $37.4M | Buy |
1,330,820
+579,331
| +77% | +$16.5M | 1.15% | 25 |
|
|
2015
Q4 | $23M | Buy |
+751,489
| New | +$23.6M | 0.66% | 36 |
|
Other funds holding PFE
Migdal Insurance & Financial Holdings's PFE Position: Q2 2025 in Review
Migdal Insurance & Financial Holdings sold out of Pfizer (PFE) in Q2 2025, closing a stake of 801,589 shares — an estimated $20.3M sold.
Migdal Insurance & Financial Holdings first reported a position in PFE in Q4 2015 and held it in 35 quarters. The position peaked at $113M in Q4 2021. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.
- Migdal Insurance & Financial Holdings reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
- Migdal Insurance & Financial Holdings sold 801,589 Pfizer shares in Q2 2025, an estimated $20.3M.
- Migdal Insurance & Financial Holdings first reported a position in Pfizer in Q4 2015 and held it in 35 quarters.
- Migdal Insurance & Financial Holdings's Pfizer position peaked at $113M in Q4 2021.
- 2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.
Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2025, filed 4 Aug 2025.